These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

210 related articles for article (PubMed ID: 19754853)

  • 1. Effects of atorvastatin on circulating CD34+/CD133+/ CD45- progenitor cells and indices of angiogenesis (vascular endothelial growth factor and the angiopoietins 1 and 2) in atherosclerotic vascular disease and diabetes mellitus.
    Jaumdally RJ; Goon PK; Varma C; Blann AD; Lip GY
    J Intern Med; 2010 Apr; 267(4):385-93. PubMed ID: 19754853
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Abnormal angiopoietins 1&2, angiopoietin receptor Tie-2 and vascular endothelial growth factor levels in hypertension: relationship to target organ damage [a sub-study of the Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT)].
    Nadar SK; Blann A; Beevers DG; Lip GY
    J Intern Med; 2005 Oct; 258(4):336-43. PubMed ID: 16164572
    [TBL] [Abstract][Full Text] [Related]  

  • 3. High-dose atorvastatin improves hypercholesterolemic coronary endothelial dysfunction without improving the angiogenic response.
    Boodhwani M; Nakai Y; Voisine P; Feng J; Li J; Mieno S; Ramlawi B; Bianchi C; Laham R; Sellke FW
    Circulation; 2006 Jul; 114(1 Suppl):I402-8. PubMed ID: 16820608
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Two types of circulating endothelial progenitor cells in patients receiving long term therapy by HMG-CoA reductase inhibitors.
    Deschaseaux F; Selmani Z; Falcoz PE; Mersin N; Meneveau N; Penfornis A; Kleinclauss C; Chocron S; Etievent JP; Tiberghien P; Kantelip JP; Davani S
    Eur J Pharmacol; 2007 May; 562(1-2):111-8. PubMed ID: 17320859
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Plasma vascular endothelial growth factor, angiopoietin-2, and soluble angiopoietin receptor tie-2 in diabetic retinopathy: effects of laser photocoagulation and angiotensin receptor blockade.
    Lip PL; Chatterjee S; Caine GJ; Hope-Ross M; Gibson J; Blann AD; Lip GY
    Br J Ophthalmol; 2004 Dec; 88(12):1543-6. PubMed ID: 15548809
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Statin therapy improves brachial artery vasodilator function in patients with Type 1 diabetes and microalbuminuria.
    Dogra GK; Watts GF; Chan DC; Stanton K
    Diabet Med; 2005 Mar; 22(3):239-42. PubMed ID: 15717868
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Plasma angiopoietin-1, angiopoietin-2, angiopoietin receptor tie-2, and vascular endothelial growth factor levels in acute coronary syndromes.
    Lee KW; Lip GY; Blann AD
    Circulation; 2004 Oct; 110(16):2355-60. PubMed ID: 15302795
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Differential effect of atorvastatin and fenofibrate on plasma oxidized low-density lipoprotein, inflammation markers, and cell adhesion molecules in patients with type 2 diabetes mellitus.
    Hogue JC; Lamarche B; Tremblay AJ; Bergeron J; Gagné C; Couture P
    Metabolism; 2008 Mar; 57(3):380-6. PubMed ID: 18249211
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A 52-week, randomized, open-label, parallel-group comparison of the tolerability and effects of pitavastatin and atorvastatin on high-density lipoprotein cholesterol levels and glucose metabolism in Japanese patients with elevated levels of low-density lipoprotein cholesterol and glucose intolerance.
    Sasaki J; Ikeda Y; Kuribayashi T; Kajiwara K; Biro S; Yamamoto K; Ageta M; Kobori S; Saikawa T; Otonari T; Kono S
    Clin Ther; 2008 Jun; 30(6):1089-101. PubMed ID: 18640465
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Systemic and intracardiac vascular endothelial growth factor and angiopoietin-1 and -2 levels in coronary artery disease: effects of angioplasty.
    Jaumdally RJ; Varma C; Blann AD; MacFadyen RJ; Lip GY
    Ann Med; 2007; 39(4):298-305. PubMed ID: 17558601
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Involvement of circulating endothelial progenitor cells and vasculogenic factors in the pathogenesis of diabetic retinopathy.
    Lee IG; Chae SL; Kim JC
    Eye (Lond); 2006 May; 20(5):546-52. PubMed ID: 15905870
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of atorvastatin on kidney outcomes and cardiovascular disease in patients with diabetes: an analysis from the Collaborative Atorvastatin Diabetes Study (CARDS).
    Colhoun HM; Betteridge DJ; Durrington PN; Hitman GA; Neil HA; Livingstone SJ; Charlton-Menys V; DeMicco DA; Fuller JH;
    Am J Kidney Dis; 2009 Nov; 54(5):810-9. PubMed ID: 19540640
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of rosiglitazone alone and in combination with atorvastatin on nontraditional markers of cardiovascular disease in patients with type 2 diabetes mellitus.
    Chu CS; Lee KT; Lee MY; Su HM; Voon WC; Sheu SH; Lai WT
    Am J Cardiol; 2006 Mar; 97(5):646-50. PubMed ID: 16490430
    [TBL] [Abstract][Full Text] [Related]  

  • 14. LDL-C/HDL-C ratio in subjects with cardiovascular disease and a low HDL-C: results of the RADAR (Rosuvastatin and Atorvastatin in different Dosages And Reverse cholesterol transport) study.
    Jukema JW; Liem AH; Dunselman PH; van der Sloot JA; Lok DJ; Zwinderman AH
    Curr Med Res Opin; 2005 Nov; 21(11):1865-74. PubMed ID: 16307708
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and safety of combination of extended release niacin and atorvastatin in patients with low levels of high density lipoprotein cholesterol.
    Harikrishnan S; Rajeev E; Tharakan JA; Titus T; Ajit Kumar VK; Sivasankaran S; Krishnamoorthy KM; Nair K
    Indian Heart J; 2008; 60(3):215-22. PubMed ID: 19240310
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of atorvastatin on endothelial function and inflammation in long-duration type 1 diabetic patients without coronary heart disease and arterial hypertension.
    Konduracka E; Galicka-Latala D; Cieslik G; Rostoff P; Fedak D; Sieradzki J; Naskalski J; Piwowarska W
    Diabetes Obes Metab; 2008 Sep; 10(9):719-25. PubMed ID: 17941871
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Atorvastatin treatment improves endothelial function through endothelial progenitor cells mobilization in ischemic heart failure patients.
    Oikonomou E; Siasos G; Zaromitidou M; Hatzis G; Mourouzis K; Chrysohoou C; Zisimos K; Mazaris S; Tourikis P; Athanasiou D; Stefanadis C; Papavassiliou AG; Tousoulis D
    Atherosclerosis; 2015 Feb; 238(2):159-64. PubMed ID: 25525743
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of lowering LDL cholesterol substantially below currently recommended levels in patients with coronary heart disease and diabetes: the Treating to New Targets (TNT) study.
    Shepherd J; Barter P; Carmena R; Deedwania P; Fruchart JC; Haffner S; Hsia J; Breazna A; LaRosa J; Grundy S; Waters D
    Diabetes Care; 2006 Jun; 29(6):1220-6. PubMed ID: 16731999
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Circulating angiopoietin-2 in essential hypertension: relation to atherosclerosis, vascular inflammation, and treatment with olmesartan/pravastatin.
    David S; Kümpers P; Lukasz A; Kielstein JT; Haller H; Fliser D
    J Hypertens; 2009 Aug; 27(8):1641-7. PubMed ID: 19390459
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Decreased circulating Fas ligand in patients with familial combined hyperlipidemia or carotid atherosclerosis: normalization by atorvastatin.
    Blanco-Colio LM; Martín-Ventura JL; Sol JM; Díaz C; Hernández G; Egido J
    J Am Coll Cardiol; 2004 Apr; 43(7):1188-94. PubMed ID: 15063428
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.